Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02474160 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later May 4, 2026 → May 4, 2028
See other at-risk trials from National Cancer Institute LAO

Record History

The 50 most recent of 129 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from May 4, 2026 to May 4, 2028 Study sites: 140 to 139 · Eligibility criteria expanded, about 37 words Show 2 more changesShow less
    • Study sites: 140 to 139
    • Eligibility criteria expanded, about 37 words
  2. Re-verified, no change to tracked fieldsv128
  3. Lead sponsor: National Cancer Institute (NCI) to National Cancer Institute LAO Eligibility criteria expanded, about 76 words · Study sites revised (140)v127 Show 2 more changesShow less
    • Eligibility criteria expanded, about 76 words
    • Study sites revised (140)

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites revised (140)v126 See this version in full on ClinicalTrials.gov ↗
  5. Re-verified, no change to tracked fieldsv125
Show 45 earlier versionsHide 45 earlier versions
  1. Primary and study completion dates: May 4, 2024 to May 4, 2026v124
  2. Site contacts updated at 1 of 140 sitesv123
  3. Site details revised at 1 of 140 sitesv122
  4. Study sites revised (140)v121 See this version in full on ClinicalTrials.gov ↗
  5. Site details revised at 1 of 140 sitesv120
  6. 2 versions Re-verified since Jan 23, 2024, no change to tracked fieldsv118-v119
  7. Study sites revised (140)v117 See this version in full on ClinicalTrials.gov ↗
  8. Site details revised at 3 of 140 sitesv116
  9. 2 versions Re-verified since Dec 15, 2023, no change to tracked fieldsv114-v115
  10. Start date: May 15, 2015 to May 19, 2015 Eligibility criteria expanded, about 84 words · Study sites revised (140)v113 Show 2 more changesShow less
    • Eligibility criteria expanded, about 84 words
    • Study sites revised (140)

    See this version in full on ClinicalTrials.gov ↗

  11. Study sites revised (140)v112 See this version in full on ClinicalTrials.gov ↗
  12. Site contacts updated at 1 of 140 sitesv111
  13. Re-verified, no change to tracked fieldsv110
  14. Site contacts updated at 3 of 140 sitesv109
  15. Re-verified, no change to tracked fieldsv108
  16. Site details revised at 1 of 140 sitesv107
  17. Site details revised at 1 of 140 sitesv106
  18. Re-verified, no change to tracked fieldsv105
  19. Primary and study completion dates: May 4, 2023 to May 4, 2024v104
  20. Site contacts updated at 1 of 140 sitesv103
  21. Study sites revised (140)v102 See this version in full on ClinicalTrials.gov ↗
  22. 2 versions Re-verified since Nov 16, 2022, no change to tracked fieldsv100-v101
  23. Site details revised at 2 of 140 sitesv99
  24. Site details revised at 2 of 140 sitesv98
  25. Re-verified, no change to tracked fieldsv97
  26. Site details revised at 1 of 140 sitesv96
  27. Study sites revised (140)v95 See this version in full on ClinicalTrials.gov ↗
  28. Re-verified, no change to tracked fieldsv94
  29. Primary and study completion dates: May 4, 2022 to May 4, 2023v93
  30. Re-verified, no change to tracked fieldsv92
  31. Site details revised at 1 of 140 sitesv91
  32. Site details revised at 1 of 140 sitesv90
  33. 3 versions Re-verified since Nov 25, 2021, no change to tracked fieldsv87-v89
  34. Completion date: May 4, 2022v86
  35. Site details revised at 2 of 140 sitesv85
  36. Site details revised at 2 of 140 sitesv84
  37. Site contacts updated at 2 of 140 sitesv83
  38. Site contacts updated at 1 of 140 sitesv82
  39. Primary completion date: May 4, 2021 to May 4, 2022v81
  40. Site details revised at 1 of 140 sitesv80
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.
Trial Details
NCT Number NCT02474160
Lead Sponsor National Cancer Institute LAO
Collaborators: National Cancer Institute (NCI)
Conditions Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov